Colorectal Cancer, Neoadjuvant
AGENAgenus Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Botensilimab/Balstilimab (AGEN1181/AGEN2034) (CTLA-4/PD-1 Blockade) in Colorectal Cancer, Neoadjuvant. The expected timing is based on the latest available company guidance and may change.
03/16/26:- Phase 2 neoadjuvant colorectal cancer trial updates expected in 2026. 05/11/26:- PR No update. 07/17/26:- NEOASIS dMMR neoadjuvant CRC data poster at ESMO on October 25, 2026. 08/06/26:- NEST and UNICORN follow-up manuscripts expected H2 2026; ROBBIN dosing expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.